T. Kim

发表

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer

Jae Hyun Kim, S. Lee, S. Im, 2008, British Journal of Cancer.

The anti‐diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo

C. Huh, Il-dong Choi, J. Sim, 2014, Journal of applied microbiology.

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone.

Y. Bang, D. Heo, S. Im, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

Jin‐Young Jang, Y. Bang, S. Im, 2016, Clinical and Translational Oncology.

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy

Seung-Yong Jeong, Y. Bang, N. Cho, 2013, British Journal of Cancer.

Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE

S. Bae, D. Yoo, T. Kim, 2002, Lupus.

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

S. Im, K. Lee, N. Kim, 2009, British Journal of Cancer.

A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.

Y. Bang, D. Heo, K. Choe, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, Administered Daily in Patients With Advanced Solid Tumors

Yoon-Koo Kang, Sang-We Kim, T. Werner, 2021 .

LBA21 Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study)

C. Sofocleous, M. Mulcahy, P. Ross, 2021, Annals of Oncology.

Management of gastric lymphoma with chemotherapy alone

T. Kim, D. Heo, D. Oh, 2005, Leukemia & lymphoma.

The beneficial effect of palliative resection in metastatic colorectal cancer

S. Im, G. Kang, D. Oh, 2013, British Journal of Cancer.

Mixed Connective Tissue Disease Associated with Skin Defects of Livedoid Vasculitis

J. Jun, C. Park, T. Kim, 2000, Clinical Rheumatology.

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location

N. Cho, J. H. Kim, G. Kang, 2013, British Journal of Cancer.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

S. Peters, S. Senan, D. Tan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

A. Blackler, C. Ock, S. Thyparambil, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer

S. Im, Tae-You Kim, T. Kim, 2014, Oncogene.

LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2

K. Blackwell, J. Kim, S. Verma, 2016 .

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†

Y. Shimada, E. Van Cutsem, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis

D. Bang, T. Kim, K-H Lee, 2014, Oncogene.

DNA hypermethylation in gastric cancer

G. Kang, T. Kim, Y. Bang, 2004, Alimentary pharmacology & therapeutics.

PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer

W. H. Kim, H. Youn, Y.J. Choi, 2014, Oncogene.

Shear-wave velocity for colorectal cancer liver metastases as a potential prognostic factor after chemotherapy: a preliminary study.

I. Joo, K. Lee, T. Kim, 2021, Clinical radiology.

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

Y. Bang, S. Im, D. Oh, 2009, British Journal of Cancer.

Seronegative Spondyloarthropathy Initiated by Physical Trauma

J. Jun, D. Yoo, T. Kim, 2000, Clinical Rheumatology.

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.

J. Berlin, M. Thomas, A. Santoro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives

Y. Bang, Dong-Wan Kim, D. Heo, 2008, British Journal of Cancer.

Postoperative chemoradiotherapy for gallbladder cancer

Y. Bang, D. Oh, Tae-You Kim, 2012, Strahlentherapie und Onkologie.

381P A tumor-informed, hybrid-capture based ctDNA assay for minimal residual disease (MRD) detection in colorectal cancer (CRC) patients after curative surgery

Y. Kim, T. Kim, S. Oh, 2022, Annals of Oncology.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

H. Iwata, F. Cardoso, J. Kim, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

M. Ducreux, A. Cheng, S. Qin, 2021, Zeitschrift für Gastroenterologie.

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC).

J. Kim, K. Rau, C. Yen, 2018, Annals of Oncology.

1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC

M. Kudo, P. Galle, M. Ducreux, 2020 .

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group.

Yoon-Koo Kang, D. Heo, Jun Suk Kim, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.